Literature DB >> 12670557

Time trends in biochemical recurrence after radical prostatectomy: results of the SEARCH database.

Stephen J Freedland1, Joseph C Presti, Christopher L Amling, Christopher J Kane, William J Aronson, Frederick Dorey, Martha K Terris.   

Abstract

OBJECTIVES: To determine whether in the prostate-specific antigen (PSA) era stage and/or grade migration of patients treated with radical prostatectomy (RP) has occurred. We also examined whether the biochemical recurrence rates after RP have changed with time.
METHODS: A total of 1654 patients from the Shared Equal Access Regional Cancer Hospital (SEARCH) database were analyzed for time trends in age, preoperative PSA level, clinical stage, biopsy Gleason score, prostatectomy Gleason grade, pathologic stage, margin status, and recurrence rates after RP. Results were stratified into three 4-year blocks of time between 1988 and 2002 for analysis.
RESULTS: The preoperative PSA level, patient age, tumor stage, rate of capsular penetration, and lymph node involvement decreased with time. Both biopsy and pathologic Gleason grade steadily increased with time. The positive margin rate and incidence of seminal vesicle involvement remained stable. On multivariate analysis, only serum PSA level (P <0.001) and biopsy Gleason score (P <0.001) were significant independent predictors of the time to recurrence after RP. The year of surgery was not a significant independent predictor of biochemical recurrence after RP in multivariate analysis.
CONCLUSIONS: Despite lower stage and lower PSA levels with time, we found no improvement in PSA recurrence rates over time. This may reflect lead-time bias in detecting PSA recurrence by the use of more sensitive PSA assays in recent years.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12670557     DOI: 10.1016/s0090-4295(02)02526-8

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  34 in total

1.  68Ga-PSMA PET/CT and Volumetric Morphology of PET-Positive Lymph Nodes Stratified by Tumor Differentiation of Prostate Cancer.

Authors:  Maria Vinsensia; Peter L Chyoke; Boris Hadaschik; Tim Holland-Letz; Jan Moltz; Klaus Kopka; Isabel Rauscher; Walter Mier; Markus Schwaiger; Uwe Haberkorn; Tobias Mauer; Clemens Kratochwil; Matthias Eiber; Frederik L Giesel
Journal:  J Nucl Med       Date:  2017-06-21       Impact factor: 10.057

Review 2.  PET/MR in prostate cancer: technical aspects and potential diagnostic value.

Authors:  Michael Souvatzoglou; Matthias Eiber; Axel Martinez-Moeller; Sebastian Fürst; Konstantin Holzapfel; Tobias Maurer; Sibylle Ziegler; Stephan Nekolla; Markus Schwaiger; Ambros J Beer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-05-24       Impact factor: 9.236

3.  Clinical trials: nationally representative data in urology.

Authors:  Jay B Shah; Vitaly Margulis
Journal:  Nat Rev Urol       Date:  2009-07       Impact factor: 14.432

4.  (11)C-Choline PET/CT for restaging prostate cancer. Results from 4,426 scans in a single-centre patient series.

Authors:  Tiziano Graziani; Francesco Ceci; Paolo Castellucci; Giulia Polverari; Giacomo Maria Lima; Filippo Lodi; Alessio Giuseppe Morganti; Andrea Ardizzoni; Riccardo Schiavina; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-06-08       Impact factor: 9.236

5.  (68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate?

Authors:  Francesco Ceci; Christian Uprimny; Bernhard Nilica; Llanos Geraldo; Dorota Kendler; Alexander Kroiss; Jasmin Bektic; Wolfgang Horninger; Peter Lukas; Clemens Decristoforo; Paolo Castellucci; Stefano Fanti; Irene J Virgolini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-05-15       Impact factor: 9.236

6.  Does salvage radiation therapy change the biology of recurrent prostate cancer based on PSA doubling times? Results from the SEARCH database.

Authors:  Roberto L Muller; Joseph C Presti; William J Aronson; Martha K Terris; Christopher J Kane; Christopher L Amling; Stephen J Freedland
Journal:  Urology       Date:  2012-03-23       Impact factor: 2.649

Review 7.  Imaging of prostate cancer with PET/CT using (18)F-Fluorocholine.

Authors:  Reza Vali; Wolfgang Loidl; Christian Pirich; Werner Langesteger; Mohsen Beheshti
Journal:  Am J Nucl Med Mol Imaging       Date:  2015-01-15

8.  Prospective head-to-head comparison of 11C-choline-PET/MR and 11C-choline-PET/CT for restaging of biochemical recurrent prostate cancer.

Authors:  Matthias Eiber; Isabel Rauscher; Michael Souvatzoglou; Tobias Maurer; Markus Schwaiger; Konstantin Holzapfel; Ambros J Beer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-08-12       Impact factor: 9.236

9.  Is the detection rate of 18F-choline PET/CT influenced by androgen-deprivation therapy?

Authors:  Sotirios Chondrogiannis; Maria Cristina Marzola; Alice Ferretti; Gaia Grassetto; Anna Margherita Maffione; Lucia Rampin; Stefano Fanti; Francesco Giammarile; Domenico Rubello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-02-25       Impact factor: 9.236

10.  (11)C-Choline PET/CT in patients with hormone-resistant prostate cancer showing biochemical relapse after radical prostatectomy.

Authors:  Francesco Ceci; Paolo Castellucci; Marcelo Mamede; Riccardo Schiavina; Domenico Rubello; Chiara Fuccio; Valentina Ambrosini; Stefano Boschi; Giuseppe Martorana; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-11-14       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.